PHASE 1B STUDY OF THE SRC INHIBITOR DASATINIB WITH FOLFOX AND CETUXIMAB IN REFRACTORY METASTATIC COLORECTAL CANCER

被引：0
|
作者：
Kopetz, S. [1 ]
Wolff, R. [1 ]
Eng, C. [1 ]
Overman, M. [1 ]
Henry, L. [1 ]
Coulson, R. [1 ]
Garrett, C. [1 ]
Abbruzzese, J. [1 ]
Gallick, G. [1 ]
机构：
[1] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：14 / 15
页数：2
相关论文
共 50 条
  • [31] Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer
    Braghiroli, Maria Ignez Freitas Melro
    Filho, Daniel Santos Rocha Sobral
    Fagundes, Juliana Goes Martins
    Mendoza, Elizabeth Zambrano
    Neffa, Maria Fernanda Batistuzzo Vicentini
    Campos, Karla Souza
    da Fonseca, Leonardo Gomes
    Bonadio, Renata Colombo
    Talans, Aley
    Braghiroli, Oddone Freitas Melro
    Mathias-Machado, Maria Cecilia
    Sabbaga, Jorge
    Venchiarutti, Camila Motta
    Hoff, Paulo Marcelo Gehm
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 42
  • [32] Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src
    Perez, Marco
    Lucena-Cacace, Antonio
    Miguel Marin-Gomez, Luis
    Padillo-Ruiz, Javier
    Jose Robles-Frias, Maria
    Saez, Carmen
    Garcia-Carbonero, Rocio
    Carnero, Amancio
    ONCOTARGET, 2016, 7 (22) : 33111 - 33124
  • [33] A Phase II Trial of FOLFOX6 and Cetuximab in the First-line Treatment of Patients With Metastatic Colorectal Cancer
    Boccia, Ralph V.
    Cosgriff, Thomas M.
    Headley, David L.
    Badarinath, Suprith
    Dakhil, Shaker R.
    CLINICAL COLORECTAL CANCER, 2010, 9 (02) : 102 - 107
  • [34] A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors
    Niharika B. Mettu
    Donna Niedzwiecki
    Christel Rushing
    Andrew B. Nixon
    Jingquan Jia
    Sherri Haley
    Wanda Honeycutt
    Herbert Hurwitz
    Johanna C. Bendell
    Hope Uronis
    Cancer Chemotherapy and Pharmacology, 2019, 83 : 1025 - 1035
  • [35] A first-in-human phase 1b study of a novel allosteric extracellular FGFR2 inhibitor alofanib in patients with refractory metastatic gastric cancer
    Tjulandin, Sergei
    Statsenko, Galina
    Artamonova, Elena
    Vladimirova, Liubov Yu
    Besova, Natalia
    Mochalova, Anastasia
    Rykov, Ivan
    Moiseyenko, Vladimir
    Utyashev, Igor A.
    Iugai, Sergei
    Kazey, Vasily
    Raskin, Grigory
    Dragun, Nadezhda
    Reznikov, Dmitry
    Gavrilova, Evgenia
    Tsimafeyeu, Ilya
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [36] Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: Preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer
    Dasari, Arvind
    Hubbard, Joleen M.
    Eng, Cathy
    Yeckes-Rodin, Heather
    Ukrainskyj, Stacey M.
    Yang, Zhao
    Schelman, William R.
    Kania, Marek K.
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [37] Genistein combined with FOLFOX or FOLFOX–Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study
    Sofya Pintova
    Sirish Dharmupari
    Erin Moshier
    Nicole Zubizarreta
    Celina Ang
    Randall F. Holcombe
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 591 - 598
  • [38] Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer
    Reidy, Diane Lauren
    Vakiani, Efsevia
    Fakih, Marwan G.
    Saif, Muhammad Wasif
    Hecht, Joel Randolph
    Goodman-Davis, Noah
    Hollywood, Ellen
    Shia, Jinru
    Schwartz, Jonathan
    Chandrawansa, Kumari
    Dontabhaktuni, Aruna
    Youssoufian, Hagop
    Solit, David B.
    Saltz, Leonard B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) : 4240 - 4246
  • [39] Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
    Jayesh Desai
    Guzman Alonso
    Se Hyun Kim
    Andres Cervantes
    Thomas Karasic
    Laura Medina
    Einat Shacham-Shmueli
    Rasha Cosman
    Alejandro Falcon
    Eelke Gort
    Tormod Guren
    Erminia Massarelli
    Wilson H. Miller
    Luis Paz-Ares
    Hans Prenen
    Alessio Amatu
    Chiara Cremolini
    Tae Won Kim
    Victor Moreno
    Sai-Hong I. Ou
    Alessandro Passardi
    Adrian Sacher
    Armando Santoro
    Rafal Stec
    Susanna Ulahannan
    Kathryn Arbour
    Patricia Lorusso
    Jia Luo
    Manish R. Patel
    Yoonha Choi
    Zhen Shi
    Sandhya Mandlekar
    Mark T. Lin
    Stephanie Royer-Joo
    Julie Chang
    Tomi Jun
    Neekesh V. Dharia
    Jennifer L. Schutzman
    Sae-Won Han
    Nature Medicine, 2024, 30 : 271 - 278
  • [40] Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
    Desai, Jayesh
    Alonso, Guzman
    Kim, Se Hyun
    Cervantes, Andres
    Karasic, Thomas
    Medina, Laura
    Shacham-Shmueli, Einat
    Cosman, Rasha
    Falcon, Alejandro
    Gort, Eelke
    Guren, Tormod
    Massarelli, Erminia
    Miller Jr, Wilson H.
    Paz-Ares, Luis
    Prenen, Hans
    Amatu, Alessio
    Cremolini, Chiara
    Kim, Tae Won
    Moreno, Victor
    Ou, Sai-Hong I.
    Passardi, Alessandro
    Sacher, Adrian
    Santoro, Armando
    Stec, Rafal
    Ulahannan, Susanna
    Arbour, Kathryn
    Lorusso, Patricia
    Luo, Jia
    Patel, Manish R.
    Choi, Yoonha
    Shi, Zhen
    Mandlekar, Sandhya
    Lin, Mark T.
    Royer-Joo, Stephanie
    Chang, Julie
    Jun, Tomi
    Dharia, Neekesh V.
    Schutzman, Jennifer L.
    Han, Sae-Won
    NATURE MEDICINE, 2023, 30 (1) : 271 - 278
12345